Brynn Hollingsworth1, Leigha Senter1, Xiaoli Zhang1, Guy N Brock1, Wael Jarjour1, Rebecca Nagy1, Pamela Brock1, Kevin R Coombes1, Richard T Kloos1, Matthew D Ringel1, Jennifer Sipos1, Ilene Lattimer1, Ricardo Carrau1, Sissy M Jhiang1. 1. Department of Physiology and Cell Biology (B.H., S.M.J.), Human Cancer Genetics Program, Comprehensive Cancer Center (L.S., R.N., P.B., I.L.), Center for Biostatistics (X.Z., G.N.B.), Department of Internal Medicine, Division of Rheumatology and Immunology (W.J.), Department of Biomedical Informatics (X.Z., G.N.B., K.R.C.), Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism (R.K., M.D.R., J.S.), Department of Internal Medicine, Division of Oncology (M.D.R.), and Department of Otolaryngology-Head & Neck Surgery (R.C.), The Ohio State University, Columbus, Ohio 43210.
Abstract
CONTEXT: Sialadenitis and xerostomia are major adverse effects of 131I therapy in thyroid cancer patients. The risk factors for these adverse effects, other than administered activity of 131I, have not been investigated. OBJECTIVE: The aim of this study is to identify risk factors for 131I-induced salivary gland damage among follicular cell-derived thyroid cancer patients. DESIGN: We enrolled 216 thyroid cancer patients who visited The Ohio State University Wexner Medical Center between April 2013 and April 2014. Symptoms of xerostomia and sialadenitis were identified via questionnaire and medical record search. To validate the findings in a large cohort, we retrospectively searched for ICD-9/10 codes for sialadenitis, xerostomia, and autoimmune disease associated with Sjögren's syndrome (AID-SS) in our existing database (n = 1507). Demographic and clinical information was extracted from medical records. Multivariate analyses were performed to identify independent predictors for salivary gland damage. RESULTS: 131I treatment associated with higher incidence of xerostomia and sialadenitis. Patients with xerostomia had 46 mCi higher mean cumulative 131I activity and 21 mCi higher mean first-administered 131I activity than patients without xerostomia. Increased age associated with higher incidence of xerostomia, and females had a higher incidence of sialadenitis. Patients who experienced sialadenitis before 131I therapy had higher sialadenitis incidence after 131I therapy. 131I-treated patients diagnosed with AID-SS, whether before or after 131I treatment, had a higher incidence of xerostomia and sialadenitis among 131I-treated patients. CONCLUSION: Risk factors for 131I-induced salivary gland damage include administered 131I activity, age, gender, history of sialadenitis before 131I treatment, and AID-SS diagnosis.
CONTEXT: Sialadenitis and xerostomia are major adverse effects of 131I therapy in thyroid cancerpatients. The risk factors for these adverse effects, other than administered activity of 131I, have not been investigated. OBJECTIVE: The aim of this study is to identify risk factors for 131I-induced salivary gland damage among follicular cell-derived thyroid cancerpatients. DESIGN: We enrolled 216 thyroid cancerpatients who visited The Ohio State University Wexner Medical Center between April 2013 and April 2014. Symptoms of xerostomia and sialadenitis were identified via questionnaire and medical record search. To validate the findings in a large cohort, we retrospectively searched for ICD-9/10 codes for sialadenitis, xerostomia, and autoimmune disease associated with Sjögren's syndrome (AID-SS) in our existing database (n = 1507). Demographic and clinical information was extracted from medical records. Multivariate analyses were performed to identify independent predictors for salivary gland damage. RESULTS:131I treatment associated with higher incidence of xerostomia and sialadenitis. Patients with xerostomia had 46 mCi higher mean cumulative 131I activity and 21 mCi higher mean first-administered 131I activity than patients without xerostomia. Increased age associated with higher incidence of xerostomia, and females had a higher incidence of sialadenitis. Patients who experienced sialadenitis before 131I therapy had higher sialadenitis incidence after 131I therapy. 131I-treated patients diagnosed with AID-SS, whether before or after 131I treatment, had a higher incidence of xerostomia and sialadenitis among 131I-treated patients. CONCLUSION: Risk factors for 131I-induced salivary gland damage include administered 131I activity, age, gender, history of sialadenitis before 131I treatment, and AID-SS diagnosis.
Authors: Megan E Daly; Yeeyie Lieskovsky; Todd Pawlicki; Jervis Yau; Harlan Pinto; Michael Kaplan; Willard E Fee; Albert Koong; Don R Goffinet; Lei Xing; Quynh-Thu Le Journal: Head Neck Date: 2007-03 Impact factor: 3.147
Authors: Krista M D La Perle; Dong Chul Kim; Nathan C Hall; Adam Bobbey; Daniel H Shen; Rebecca S Nagy; Paul E Wakely; Amy Lehman; David Jarjoura; Sissy M Jhiang Journal: Thyroid Date: 2013-07-17 Impact factor: 6.568
Authors: Brynn A Hollingsworth; David R Cassatt; Andrea L DiCarlo; Carmen I Rios; Merriline M Satyamitra; Thomas A Winters; Lanyn P Taliaferro Journal: Front Pharmacol Date: 2021-05-18 Impact factor: 5.810